premenstrual dysphoric disorder (PMDD)
Start with the big picture
PMDD is associated with abnormal central nervous system sensitivity to normal ovarian hormone fluctuations, with serotonin dysregulation serving as a key pharmacologic target. DSM-5 diagnosis requires at least five symptoms, including at least one mood symptom, across most cycles for 12 months, with functional impairment and prospective confirmation over two cycles. Assessment also considers alternative explanations and medication triggers. Management begins with non-pharmacologic strategies such as cognitive behavioral therapy, exercise, and sleep hygiene. SSRIs are first-line pharmacotherapy and may be given continuously, during the luteal phase, or from symptom onset. The broader lesson reviews alternatives, safety considerations, monitoring, and patient expectations.
What you'll learn
- Describe PMDD’s cyclic symptom pattern and its impact on functioning.
- Summarize the proposed pathophysiology and serotonin’s treatment relevance.
- Identify the core DSM-5 diagnostic requirements and need for prospective confirmation.
- Compare non-pharmacologic strategies with first-line SSRI approaches.
- Recognize alternative treatments and key safety considerations.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
